2-(2-Ethoxyphenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

CAS: 224789-21-3

Ref. 3D-FE11061

Produktinformation

• Name: 2-(2-Ethoxyphenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• Synonyme: 2-(2-Ethoxyphenyl)-5-Methyl-7-Propyl-3H-Imidazol[5,1-F][1,2,4]-Triazin-4-One, 2-(2-Ethoxyphenyl)-5-Methyl-7-Propylimidazo[5,1-F][1,2,4]Triazin-4-Ol, 2-(2-Ethoxyphenyl)-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one, 2-(2-Ethoxyphenyl)-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one, Imidazo[5,1-F][1,2,4]Triazin-4-Ol, 2-(2-Ethoxyphenyl)-5-Methyl-7-Propyl-, imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-(2-ethoxyphenyl)-5-methyl-7-propyl-, imidazo[5,1-f][1,2,4]triazin-4(3H)-one, 2-(2-ethoxyphenyl)-5-methyl-7-propyl-

Beschreibung

2-(2-Ethoxyphenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (MIA) is a competitive inhibitor of phosphodiesterase type 5 (PDE5). The recovery and validation of MIA was performed by analyzing the drug in human serum with an electrospray ionization mass spectrometer. MIA was found to be stable in human serum. MIA was quantified and its concentration was determined to be within the range of 0.02±0.04 μg/mL. This study also validated an analytical method for quantification of MIA in human serum using reversed phase HPLC with UV detection at 450 nm and reaction monitoring at m/z 214. Maintaining a calibration curve for MIA has been achieved by using sildenafil as a reference standard. The new method can be used for clinical purposes to monitor patients receiving

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 312.36 g/mol
• Formel: C₁₇H₂₀N₄O₂
• Reinheit: Min. 95%
• InChl: InChI=1S/C17H20N4O2/c1-4-8-14-18-11(3)15-17(22)19-16(20-21(14)15)12-9-6-7-10-13(12)23-5-2/h6-7,9-10H,4-5,8H2,1-3H3,(H,19,20,22)
• InChI Key: InChIKey=YRRWQMBIMZMVDB-UHFFFAOYSA-N
• SMILES: CCCc1nc(C)c2c(=O)[nH]c(-c3ccccc3OCC)nn12